6 reports

Gastric cancer

4385 5000 3900
  • Marketed Drugs: Gastric Cancer
  • Pipeline: Gastric Cancer

Pipeline therapies will look to fulfil many areas of high unmet need left by the lack of targeted therapies approved for the treatment of gastric cancer. This report addresses the following questions: - What impact will the PD-1/PD-L1 inhibitor class of drugs have on the gastric cancer market? - How will pipeline immunotherapies...

  • Cancer
  • Chemotherapy
  • Gastric Cancer
  • Therapy
  • Chugai Pharmaceutical Co., Ltd.
  • It strongly focuses on innovation of new products and marketing productivity
  • Market landscape

About colorectal cancer Colorectal cancer refers to malignancies that originate in the rectum or the colon. It is also known as bowel cancer. Formation of adenocarcinomas is the most common feature of colorectal cancer. The cancer starts as a polyp in the inner wall of the colon or rectum. These polyps can be benign or malignant. Some of...

  • Cancer
  • Japan
  • United States
  • Market Size
  • Chugai Pharmaceutical Co., Ltd.
  • 7. MARKET FORECAST AND OPPORTUNITY ANALYSIS

TARGET PATIENT POPULATION ## Metastatic Pancreatic Cancer (with high serum levels of free IGF-##) In 2014, there were an estimated ##, ## people living with pancreatic cancer in the US.

  • Cancer
  • North America
  • United States
  • Market Size
  • Chugai Pharmaceutical Co., Ltd.
  • AUG 02, 2017: FDA GRANTS GENENTECH'S ALECENSA PRIORITY REVIEW FOR INITIAL TREATMENT OF PEOPLE WITH ALK-POSITIVE LUNG CANCER
  • FEB 08, 2017: ROCHE'S ALECENSA (ALECTINIB) APPROVED IN SWITZERLAND FOR PEOPLE WITH A SPECIFIC TYPE OF LUNG CANCER

Summary Chugai Pharmaceutical Co Ltd (Chugai) is a subsidiary of Hoffmann-La Roche Ltd, which focuses on the research, development, manufacture, commercialization, import and export of the biopharmaceuticals and therapeutic antibodies.The company offers products for the treatment of cancer; bone and joint diseases; renal...

  • Cancer
  • Pharmaceutical
  • Therapy
  • Japan
  • Chugai Pharmaceutical Co., Ltd.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.
  • Chugai Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2016
  • Discontinued Pipeline Product Profiles

Chugai Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘Chugai Pharmaceutical Co., Ltd. - Product Pipeline Review, 2016’, provides an overview of the Chugai Pharmaceutical Co., Ltd.’s pharmaceutical research and development focus. The report provides comprehensive information...

  • Cancer
  • Pharmaceutical
  • Research And Development
  • Therapy
  • Chugai Pharmaceutical Co., Ltd.